Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

The private testing lab is ramping up tests at the behest of the government. In the two weeks since Quest Diagnostics began processing novel coronavirus samples in its infectious disease lab, the ...

Outbreaks have surged in the South and West in the United States. As COVID-19 test positivity rates resurged in recent weeks, private test providers have made efforts to sound the alarm that the ...

Myriad Genetics ($MYGN) is fighting back hard against rival Quest Diagnostics' ($DGX) decision to launch a new, cheaper BRCA test that challenges its own offerings ...

Quest Diagnostics, the world’s leading provider of diagnostic information services, on Monday said demand for COVID-19 tests “continues to outpace” capacity. Demand for molecular testing is highest in ...

Starting today, people in the US can order the tests on Quest's consumer testing site without visiting a doctor. At $119, the kit is one of the more expensive offered on Quest's site. It requires a ...

With demand for COVID-19 tests rapidly drying up, testmakers like Quest Diagnostics are scrambling to find deeper waters that’ll keep them from running aground. Quest, for one, is banking on its core ...

Forbes contributors publish independent expert analyses and insights. Quidel, a company that makes diagnostic products for infectious diseases and other conditions, has been the biggest winner in our ...

Quest Diagnostics is furloughing more than 4,000 employees — roughly 9% of its workforce — as the medical testing company contends with a sharp drop in business only partially offset by surging demand ...

Our indicative theme of Covid-19 Testing Stocks, which includes medical device and diagnostic companies that are involved in Covid-19 testing – is up by about 66% year-to-date, significantly ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...